Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06021457 · ClinicalTrials.gov registry record · Phase 3
Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery
A Phase 3 study, sponsored by Renibus Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 454
- Enrollment target
NCT06021457 is a Phase 3 study that has completed, run by Renibus Therapeutics. The registered enrollment target is 454 participants.
The verdict
NCT06021457, a Phase 3 study, has completed, sponsored by Renibus Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 454 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of RBT-1 on reducing the risk of post-operative complications in subjects undergoing cardiac surgery on cardiopulmonary bypass (CPB). A sub-study will also be conducted to evaluate the pharmacokinetic (PK) profile of a single administration of RBT-1 by means of a popPK approach in subjects scheduled to undergo cardiac surgery.
Interventions
- DRUG Placebo
- DRUG RBT-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 454 participants |
| Start Date | 2023-10-17 |
| Est. Completion | 2025-06-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06021457
The ClinicalTrials.gov registry entry for NCT06021457 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 454 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Renibus Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06021457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06021457 about?
NCT06021457 is a clinical study titled "Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery". The purpose of this study is to evaluate the effect of RBT-1 on reducing the risk of post-operative complications in subjects undergoing cardiac surgery on cardiopulmonary bypass (CPB). A sub-study will also be conducted to evaluate the pharmacokinetic (PK) profile of a single administration of RBT-...
What is the current status of trial NCT06021457?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 454 participants. The study started on 2023-10-17. Estimated completion is 2025-06-17.
What interventions are being tested in trial NCT06021457?
The interventions under investigation include: Placebo (DRUG), RBT-1 (DRUG).
Who is sponsoring clinical trial NCT06021457?
This trial is sponsored by Renibus Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.